Cancer & SURVIVEiT News

Category Filter:

FDA approves neratinib for metastatic HER2-positive breast cancer

February 27, 2020

FDA approves neratinib for metastatic HER2-positive breast cancer On February 25, 2020, the Food and Drug Administration approved neratinib (NERLYNX, Puma Biotechnology, Inc.) in combination with capecitabine for adult patients…

Regular Exercise Can Improve Quality of Life For Breast Cancer Patients

October 25, 2019

Researchers at the University of Alberta found that regular exercise, both during and after chemotherapy, can improve the quality of life as well as cancer-related symptoms in breast cancer patients.…

How To Perform a Male Breast Exam Self-Check | Male Breast Cancer Awareness

October 15, 2019

During Breast Cancer Awareness month, it’s important to spread the word about all types of breast cancer so everyone can be familiar with the signs…and that includes men too. Men…

Link To Rare Cancer Causes Breast Implants To Be Recalled

October 10, 2019

Breast Cancer Awareness month is about bringing awareness to all aspects of breast cancer, not only the symptoms. For some breast cancer patients and breast cancer survivors, breast implants, augmentation…

Real Thoughts That Cross A Breast Cancer Patient’s Mind

October 8, 2019

The emotions that come along with a cancer diagnosis can be a rollercoaster. A common feeling that many breast cancer patients experience is fear. During Breast Cancer Awareness month we…

FDA approves entrectinib for NTRK solid tumors and ROS-1 NSCLC

September 19, 2019

FDA approves entrectinib for NTRK solid tumors and ROS-1 NSCLC On August 15, 2019, the Food and Drug Administration granted accelerated approval to entrectinib (ROZLYTREK, Genentech Inc.) for adults and…

FDA approves Herzuma as a biosimilar to Herceptin (for breast cancer)

January 15, 2019

FDA approves Herzuma as a biosimilar to Herceptin On December 14, 2018, the Food and Drug Administration approved Herzuma (trastuzumab-pkrb, Celltrion Inc.) as a biosimilar to Herceptin (trastuzumab, Genentech Inc.)…

FDA approves talazoparib for gBRCAm HER2-negative locally advanced or metastatic breast cancer

October 22, 2018

FDA approves talazoparib for gBRCAm HER2-negative locally advanced or metastatic breast cancer​ On October 16, 2018, the Food and Drug Administration approved talazoparib (TALZENNA, Pfizer Inc.), a poly (ADP-ribose) polymerase…

Study shows value of breast cancer patients seeking second opinions

September 28, 2018

Study shows value of breast cancer patients seeking second opinions As scary as a cancer diagnosis can be, pausing to get more information can yield benefits Dawn Brazell | brazell@musc.edu | September 19,…